Landínez R, Liñares J, Loza E, Martínez-Beltrán J, Martín R, Baquero F
Departamento de Microbiología, Facultad de Medicina, Universidad de Valladolid, Spain.
Eur J Clin Microbiol Infect Dis. 1992 Mar;11(3):265-7. doi: 10.1007/BF02098096.
The in vitro activity of azithromycin against human pathogenic strains of Brucella melitensis was tested at three centres and compared to that of tetracycline, the standard antibiotic currently used for the treatment of human brucellosis. MIC determination was carried out. Tested concentration ranges for both azithromycin and tetracycline were between 0.03 and 16 micrograms/ml. Brucella melitensis biotype 1, strain M16 was employed as a control microorganism. A total of 358 Brucella melitensis strains from human blood cultures were tested. MIC90 (micrograms/ml) values ranged from 0.5 to 1.00 for azithromycin and were 0.25 for tetracycline. It was concluded that there was little difference in the sensitivity of pathogenic Brucella melitensis to azithromycin and tetracycline isolated from three different regions in Spain. These results encourage further investigations on the possible therapeutic role of azithromycin in brucellosis.
在三个中心测试了阿奇霉素对人源致病性羊种布鲁氏菌菌株的体外活性，并与四环素（目前用于治疗人类布鲁氏菌病的标准抗生素）的活性进行了比较。进行了最低抑菌浓度（MIC）测定。阿奇霉素和四环素的测试浓度范围均为0.03至16微克/毫升。使用羊种布鲁氏菌生物1型菌株M16作为对照微生物。共测试了358株来自人类血培养的羊种布鲁氏菌菌株。阿奇霉素的MIC90（微克/毫升）值范围为0.5至1.00，四环素的MIC90值为0.25。得出的结论是，从西班牙三个不同地区分离出的致病性羊种布鲁氏菌对阿奇霉素和四环素的敏感性差异不大。这些结果鼓励进一步研究阿奇霉素在布鲁氏菌病治疗中的潜在作用。
